FDA approves Zanvastro as first treatment for Alexander disease

The FDA has approved Zanvastro as the first treatment for Alexander disease in paediatric and adult patients.

Zanvastro, also known as zilganersen, is the first FDA-approved therapy for Alexander disease and the first treatment designed to directly address the GFAP protein accumulation that drives the rare neurological disorder.

The approval introduces a disease-targeted treatment for patients who previously had no approved therapeutic option beyond supportive care.

Field	Content
Alert Type	Approval
Drug Name	Zilganersen
Brand Name	Zanvastro
Company	Ionis Pharmaceuticals
Regulatory Authority	U.S. Food and Drug Administration
Approval Type	New drug approval
Indication	Treatment of Alexander disease in paediatric and adult patients
Therapy Area(s)	Neurology; rare disease
Geography	United States
What Happened	The FDA approved Zanvastro (zilganersen) for the treatment of Alexander disease in paediatric and adult patients.
Why It Matters	Zanvastro is the first FDA-approved treatment for Alexander disease and the first therapy designed to directly target the underlying protein accumulation driving the disorder.
Supporting Context	Alexander disease is a rare progressive neurological disorder caused by mutations affecting glial fibrillary acidic protein, or GFAP.
Key Takeaway	FDA approval of Zanvastro establishes the first disease-targeted treatment option for people with Alexander disease.
What to Watch	Clinical adoption of Zanvastro and longer-term evidence on its impact across paediatric and adult Alexander disease populations.
Primary Source	U.S. Food and Drug Administration
Relevant Date	3 September 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com